The Investment of Arthritic Medicine
A new drug to help the symptoms of rheumatoid arthritis has entered lawmakers' scopes as is becomes a topic of controversy regarding investment issues.
A political debate over Xeljanz, produced by Pfizer, has cost taxpayers a whopping…